Skip to content
Study details
Enrolling now

Nicotinamide Riboside for Arterial Stiffness and High Blood Pressure in Kidney Disease

University of Colorado, Denver
NCT IDNCT04040959ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

118

Study length

about 4.8 years

Ages

35–80

Locations

1 site in CO

What this study is about

Researchers are testing whether nicotinamide riboside can help reduce arterial stiffness and high blood pressure in people with kidney disease. The trial will give participants either nicotinamide riboside or a placebo (inactive pill) for 3 months. Researchers will measure the stiffness of their arteries, blood pressure, and levels of certain substances related to inflammation and oxidative stress.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take Nicotinamide riboside

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
Randomized & Blinded

You may get a placebo/standard care, and you won't know which.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Endpoints

Primary: carotid-femoral pulse wave velocity

Secondary: Systolic blood pressure

Body systems

Renal